Literature DB >> 23054578

Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib.

Premal D Lulla1, Jonathan E Brammer, Salman Bandeali, Garret R Lynch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23054578     DOI： 10.1007/s12029-012-9438-6

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  10 in total

1.  Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

Authors:  Li Liu; Yichen Cao; Charles Chen; Xiaomei Zhang; Angela McNabola; Dean Wilkie; Scott Wilhelm; Mark Lynch; Christopher Carter
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

2.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

3.  Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

Authors:  Ghassan K Abou-Alfa; Lawrence Schwartz; Sergio Ricci; Dino Amadori; Armando Santoro; Arie Figer; Jacques De Greve; Jean-Yves Douillard; Chetan Lathia; Brian Schwartz; Ian Taylor; Marius Moscovici; Leonard B Saltz
Journal:  J Clin Oncol       Date:  2006-08-14       Impact factor: 44.544

4.  Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.

Authors:  Sean Xiang Wang; Abigail Byrnes; Sadhna Verma; John R Pancoast; Olivier Rixe
Journal:  Target Oncol       Date:  2010-03-23       Impact factor: 4.493

Review 5.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Andrew Burroughs; Jordi Bruix
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

6.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

8.  Complete response for advanced liver cancer during sorafenib therapy: case report.

Authors:  Rodolfo Sacco; Irene Bargellini; Giannelli Gianluigi; Marco Bertini; Elena Bozzi; Emanuele Altomare; Valentina Battaglia; Antonio Romano; Michele Bertoni; Alfonso Capria; Giampaolo Bresci; Carlo Bartolozzi
Journal:  BMC Gastroenterol       Date:  2011-01-17       Impact factor: 3.067

9.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

10.  Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report.

Authors:  Brian J So; Tanios Bekaii-Saab; Mark A Bloomston; Tushar Patel
Journal:  J Hematol Oncol       Date:  2008-10-17       Impact factor: 17.388
  10 in total
  2 in total

Review 1.  Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.

Authors:  Daizhong Liu; Aixiang Liu; Junping Peng; Yong Hu; Xielin Feng
Journal:  Eur J Med Res       Date:  2015-02-04       Impact factor: 2.175

Review 2.  Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): A case report and literature review.

Authors:  Dong Hyun Kim; Eunae Cho; Sung Bum Cho; Sung Kyu Choi; Sunmin Kim; Jieun Yu; Young-Il Koh; Da Woon Sim; Chung Hwan Jun
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.